Gene-specific
methylation status |
||||||||||||||
All
breast cancer cases |
Methylated
breast tumor |
Unmethylated
breast tumor |
||||||||||||
Genes |
Recreational physical activitya |
ER+PR+/ |
OR |
(95% CI) |
|
ER+PR+/ |
OR |
(95% CI) |
|
ER+PR+/ |
OR |
(95% CI) |
p
for interaction |
|
APC |
||||||||||||||
Inactive |
55/41 |
1.00 |
reference |
25/21 |
1.00 |
reference |
30/20 |
1.00 |
reference |
0.164 |
||||
Low RPA |
69/61 |
0.84 |
(0.50, 1.44) |
32/31 |
0.87 |
(0.40, 1.87) |
37/30 |
0.82 |
(0.39, 1.73) |
|||||
High RPA |
73/39 |
1.40 |
(0.80, 2.45) |
40/21 |
1.60 |
(0.73, 3.52) |
33/18 |
1.22 |
(0.55, 2.74) |
|||||
BRCA1 |
||||||||||||||
Inactive |
63/45 |
1.00 |
reference |
35/27 |
1.00 |
reference |
28/18 |
1.00 |
reference |
0.259 |
||||
Low RPA |
74/61 |
0.87 |
(0.52, 1.45) |
44/39 |
0.88 |
(0.45, 1.70) |
30/22 |
0.87 |
(0.39, 1.96) |
|||||
High RPA |
76/44 |
1.23 |
(0.72, 2.10) |
46/23 |
1.55 |
(0.76, 3.16) |
30/21 |
0.92 |
(0.41, 2.07) |
|||||
CDH1 |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
5/4 |
not estimated |
50/35 |
1.00 |
reference |
-- |
|||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
4/7 |
not estimated |
63/54 |
0.82 |
(0.47, 1.44) |
||||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
2/1 |
not estimated |
67/36 |
1.31 |
(0.72, 2.36) |
||||||
CYCLIND2 |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
12/13 |
1.00 |
reference |
43/26 |
1.00 |
reference |
0.115 |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
10/13 |
0.83 |
(0.26, 2.59) |
57/48 |
0.72 |
(0.39, 1.34) |
|||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
18/7 |
2.82 |
(0.87, 9.16) |
51/30 |
1.03 |
(0.53, 2.00) |
|||||
DAPK |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
11/6 |
1.00 |
reference |
44/33 |
1.00 |
reference |
0.145 |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
7/11 |
0.34 |
(0.09, 1.35) |
60/50 |
0.90 |
(0.50, 1.62) |
|||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
14/6 |
1.36 |
(0.33, 5.53) |
55/31 |
1.33 |
(0.71, 2.51) |
|||||
ESR1 |
||||||||||||||
Inactive |
63/45 |
1.00 |
reference |
30/21 |
1.00 |
reference |
33/24 |
1.00 |
reference |
0.194 |
||||
Low RPA |
73/60 |
0.87 |
(0.52, 1.45) |
32/32 |
0.70 |
(0.33, 1.47) |
41/28 |
1.06 |
(0.52, 2.18) |
|||||
High RPA |
76/44 |
1.24 |
(0.72, 2.11) |
31/15 |
1.44 |
(0.63, 3.32) |
45/29 |
1.13 |
(0.56, 2.29) |
|||||
GSTP1 |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
12/16 |
1.00 |
reference |
43/23 |
1.00 |
reference |
0.030 |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
16/10 |
2.33 |
(0.76, 7.17) |
51/51 |
0.53 |
(0.28, 1.01) |
|||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
18/11 |
2.33 |
(0.79, 6.84) |
51/26 |
1.05 |
(0.53, 2.10) |
|||||
HIN |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
33/18 |
1.00 |
reference |
22/21 |
1.00 |
reference |
0.207 |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
43/33 |
0.69 |
(0.33, 1.45) |
24/28 |
0.82 |
(0.37, 1.84) |
|||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
51/18 |
1.55 |
(0.70, 3.40) |
18/19 |
0.92 |
(0.38, 2.21) |
|||||
p16 |
||||||||||||||
Inactive |
54/41 |
1.00 |
reference |
2/2 |
not estimated |
52/39 |
1.00 |
reference |
-- |
|||||
Low RPA |
66/61 |
0.82 |
(0.48, 1.40) |
1/4 |
not estimated |
65/57 |
0.85 |
(0.49, 1.47) |
||||||
High RPA |
70/39 |
1.36 |
(0.77, 2.39) |
3/1 |
not estimated |
67/38 |
1.32 |
(0.74, 2.35) |
||||||
PR |
||||||||||||||
Inactive |
63/45 |
1.00 |
reference |
5/8 |
not estimated |
58/37 |
1.00 |
reference |
-- |
|||||
Low RPA |
74/61 |
0.87 |
(0.52, 1.45) |
4/10 |
not estimated |
70/51 |
0.88 |
(0.51, 1.52) |
||||||
High RPA |
76/44 |
1.23 |
(0.72, 2.10) |
10/5 |
not estimated |
66/39 |
1.08 |
(0.61, 1.91) |
||||||
RARB |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
13/19 |
1.00 |
reference |
42/20 |
1.00 |
reference |
0.183 |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
16/19 |
1.23 |
(0.46, 3.24) |
51/42 |
0.57 |
(0.29, 1.10) |
|||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
16/12 |
1.96 |
(0.70, 5.49) |
53/25 |
1.01 |
(0.49, 2.06) |
|||||
RASSF1A |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
49/29 |
1.00 |
reference |
6/10 |
1.00 |
reference |
-- |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
57/51 |
0.66 |
(0.36, 1.19) |
10/10 |
1.72 |
(0.44, 6.64) |
|||||
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
57/32 |
1.06 |
(0.56, 1.98) |
12/5 |
not estimated |
||||||
TWIST |
||||||||||||||
Inactive |
55/39 |
1.00 |
reference |
8/10 |
1.00 |
reference |
47/29 |
1.00 |
reference |
0.360 |
||||
Low RPA |
67/61 |
0.78 |
(0.45, 1.33) |
9/12 |
0.86 |
(0.24, 3.15) |
58/49 |
0.73 |
(0.40, 1.34) |
|||||
|
High RPA |
69/37 |
1.32 |
(0.75, 2.34) |
|
11/6 |
2.39 |
(0.61, 9.46) |
|
58/31 |
1.16 |
(0.61, 2.19) |
|
|
a Low
RPA ≤ 9.23 hours/week, High RPA > 9.23 hours/week |
||||||||||||||
Table 4: Age-adjusted odds ratios (ORs) and 95% confidence intervals
(CIs) for the association between postmenopausal recreational physical activity
(RPA) and ER+PR+ breast cancer (vs. all others: ER-PR-, ER+PR-, ER-PR+)
considering gene-specific methylation status of the tumor (methylated vs.
unmethylated), the Long Island Breast Cancer Study Project (1996-1997).